Profectus gains $6.25M in grants

Profectus BioSciences has received $6.25 million in National Institute of Allergy and Infectious Diseases grants, including $2.9 million in Small Business Innovative Research grants. The company's adjuvant profile focuses on harnessing the body's immune system to fight off viruses and cancers more effectively. Earlier this week, the company received an additional $4.4 million for its HIV vaccine. Profectus release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.